HilleVax

Hille Vax

Biotechnology, 75 State St, Boston, Massachusetts, 02109, United States, 51-200 Employees

hillevax.com

  • twitter
  • LinkedIn

phone no Phone Number: 88********

Who is HILLEVAX

HilleVax is a biopharmaceutical company focused on the development and commercialization of novel vaccines. Our initial program, HIL-214, is a virus-like particle (VLP) based vaccine cand...

Read More

map
  • 75 State St, Boston, Massachusetts, 02109, United States Headquarters: 75 State St, Boston, Massachusetts, 02109, United States
  • 2021 Date Founded: 2021
  • 51-200 Employees: 51-200
  • dollar-icon Revenue: $50 Million to $100 Million
  • tech-icon Active Tech Stack: See technologies

industries-icon Industry: Biotechnology

SIC SIC Code: 2836 | NAICS Code: 325414 | Show More

checked-icon Does something look wrong? Fix it. | View contact records from HILLEVAX

HilleVax Org Chart and Mapping

Employees

Robbie Gay

Director, Quality Systems & Compliance

Lynne Martin

Director, Quality Assurance Operations

Jennifer Trammell

Senior Director, Clinical Quality

Marlon Velasco

Sr. Director, Information Technology

Lauren Hughes

Quality Systems Manager

Lakshmi Kumar

Director, Clinical Project Management

signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

crown-icon Free credits every month

Frequently Asked Questions Regarding HilleVax

Answer: HilleVax's headquarters are located at 75 State St, Boston, Massachusetts, 02109, United States

Answer: HilleVax's phone number is 88********

Answer: HilleVax's official website is https://hillevax.com

Answer: HilleVax's revenue is $50 Million to $100 Million

Answer: HilleVax's SIC: 2836

Answer: HilleVax's NAICS: 325414

Answer: HilleVax has 51-200 employees

Answer: HilleVax is in Biotechnology

Answer: HilleVax contact info: Phone number: 88******** Website: https://hillevax.com

Answer: HilleVax is a biopharmaceutical company focused on the development and commercialization of novel vaccines. Our initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate in development for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection.

Answer:

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access